Tag: agent

CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of its underwritten public offering of 6,000,000 units, with each unit consisting of one share of common stock and one warrant (the “Warrants”) (or pre-funded units in lieu thereof, with each pre-funded unit consisting of one pre-funded warrant (the “Pre-Funded Warrants”) and one Warrant). Each unit is being sold to the public at a price of $2.00 per unit (and each pre-funded unit is being sold to the public at the public offering price of each unit less the $0.0001 per share nominal exercise price for each Pre-Funded Warrant). The gross proceeds to the Company from this offering are expected to be approximately $12 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Warrants included in the units and pre-funded units have been approved for listing on the Nasdaq Capital Market and are expected to commence trading under the symbol “BIVIW” on August 8, 2025. Each Warrant will be immediately exercisable, will entitle the holder to purchase one share of common stock at an exercise price of $2.50 per share and will expire five years from the date of issuance. Each Pre-Funded Warrant will be immediately exercisable, will entitle the holder to purchase one share of common stock and may be exercised at any time until exercised in full. The common stock (or Pre-Funded Warrants in lieu thereof) and Warrants can only be purchased together in the offering but will be issued separately. The Company has granted the underwriter a 45-day option to purchase up to an additional 900,000 shares of common stock and/or Pre-Funded Warrants and/or Warrants, or any combination thereof, solely to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions.

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Rocket Pharmaceuticals class action lawsuit – captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.) – seeks to represent purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities and charges Rocket Pharmaceuticals and one of Rocket Pharmaceuticals’ top executives with violations of the Securities Exchange Act of 1934. A subsequently filed case is captioned Yankov v. Rocket Pharmaceuticals, Inc., No. 25-cv-13532 (D.N.J.).

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Timbercreek Financial Corp. (TSX: TF) ("Timbercreek Financial" or the "Company") is pleased to announce a significant update to its credit facilities. On August 7, 2025, Timbercreek Financial entered into a second amending agreement to the third amended and restated credit agreement (the "New Credit Agreement") with a syndicate of nine lenders. The New Credit Agreement provides for revolving credit facilities totaling $600 million, including a $20 million swingline facility, up from the previous $510 million credit facility. The facility also includes a $100 million accordion feature for future expansion, subject to certain conditions. The term of the New Credit Agreement is two years, maturing on August 7, 2027. The Toronto-Dominion Bank will continue to act as sole lead arranger, sole book-runner, and administration agent.

- Halneuron^® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track as projected for Q4 2025 -

Reorganization Enables Company to Protect ~$2.7 Billion of Net Operating Losses (NOLs)